Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger

doi:10.1056/NEJMc1901535

. 2019 Jun 6;380(23):2271-2273.

doi: 10.1056/NEJMc1901535.

Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger

Affiliations

¹ Francis I. Proctor Foundation, San Francisco, CA thuy.doan@ucsf.edu.
² Carter Center, Niamey, Niger.
³ Francis I. Proctor Foundation, San Francisco, CA.

PMID: 31167060
PMCID: PMC6518950
DOI: 10.1056/NEJMc1901535

Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger

Thuy Doan et al. N Engl J Med. 2019.

. 2019 Jun 6;380(23):2271-2273.

doi: 10.1056/NEJMc1901535.

Affiliations

¹ Francis I. Proctor Foundation, San Francisco, CA thuy.doan@ucsf.edu.
² Carter Center, Niamey, Niger.
³ Francis I. Proctor Foundation, San Francisco, CA.

PMID: 31167060
PMCID: PMC6518950
DOI: 10.1056/NEJMc1901535

No abstract available

PubMed Disclaimer

Comment in

Hope and Humility for Azithromycin.
Bar-Zeev N, Moss WJ. Bar-Zeev N, et al. N Engl J Med. 2019 Jun 6;380(23):2264-2265. doi: 10.1056/NEJMe1906459. N Engl J Med. 2019. PMID: 31167057 No abstract available.
Macrolide Resistance and Longer-Term Assessment of Azithromycin in MORDOR I.
Poddighe D. Poddighe D. N Engl J Med. 2019 Nov 28;381(22):2184. doi: 10.1056/NEJMc1910014. N Engl J Med. 2019. PMID: 31774978 No abstract available.

Cited by

Minimal Impact on the Resistome of Children in Botswana After Azithromycin Treatment for Acute Severe Diarrheal Disease.
Guitor AK, Katyukhina A, Mokomane M, Lechiile K, Goldfarb DM, Wright GD, McArthur AG, Pernica JM. Guitor AK, et al. J Infect Dis. 2024 Jul 25;230(1):239-249. doi: 10.1093/infdis/jiae049. J Infect Dis. 2024. PMID: 39052715 Clinical Trial.
Feasibility and acceptability of integrating mass distribution of azithromycin to children 1-11 months into a trachoma mass drug administration campaign to reduce child mortality in Côte d'Ivoire.
Dulli L, Touré F, Mama AD, Evens E, Murray K, Djè NN, Koné S, Sadate-Ngatchou P, Bovary A, Eichleay M, Jean-Baptiste M, Méité A. Dulli L, et al. PLOS Glob Public Health. 2024 Jul 10;4(7):e0003426. doi: 10.1371/journal.pgph.0003426. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 38985785 Free PMC article.
Assessment of Spillover of Antimicrobial Resistance to Untreated Children 7-12 Years Old After Mass Drug Administration of Azithromycin for Child Survival in Niger: A Secondary Analysis of the MORDOR Cluster-Randomized Trial.
Peterson B, Arzika AM, Amza A, Maliki R, Karamba AM, Moussa M, Kemago M, Liu Z, Houpt E, Liu J, Pholwat S, Doan T, Porco TC, Keenan JD, Lietman TM, O'Brien KS. Peterson B, et al. Clin Infect Dis. 2024 Nov 22;79(5):1136-1143. doi: 10.1093/cid/ciae267. Clin Infect Dis. 2024. PMID: 38739754 Free PMC article. Clinical Trial.
Prolonged mass azithromycin distributions and macrolide resistance determinants among preschool children in Niger: A sub-study of a cluster-randomized trial (MORDOR).
Arzika AM, Abdou A, Maliki R, Beido N, Kadri B, Harouna AN, Galo AN, Alio MK, Lebas E, Oldenburg CE, O'Brien KS, Chen C, Zhong L, Zhou Z, Yan D, Hinterwirth A, Keenan JD, Porco TC, Lietman TM, Doan T; MORDOR Study Group. Arzika AM, et al. PLoS Med. 2024 May 6;21(5):e1004386. doi: 10.1371/journal.pmed.1004386. eCollection 2024 May. PLoS Med. 2024. PMID: 38709718 Free PMC article. Clinical Trial.
Four recent insights suggest the need for more refined methods to assess the resistogenicity of doxycycline post exposure prophylaxis.
Vanbaelen T, Manoharan-Basil SS, Kenyon C. Vanbaelen T, et al. Curr Res Microb Sci. 2024 Apr 8;6:100234. doi: 10.1016/j.crmicr.2024.100234. eCollection 2024. Curr Res Microb Sci. 2024. PMID: 38646593 Free PMC article.

See all "Cited by" articles

References

1. Keenan JD, Bailey RL, West SK, et al. . Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. N Engl J Med 2018;378:1583-92. - PMC - PubMed
1. O'Brien KS, Emerson P, Hooper PJ, et al. . Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis 2018. - PubMed
1. Keenan JD, Arzika AM, Abdou A, Maliki R, Kane S, Cook C, Lebas E, Lin Y, Ray KJ, O’Brien KS, Doan T, Oldenburg C, Emerson PM, Porco TC, Lietman TM. MORDOR II: Persistence of Benefit of Azithryomcin for Childhood Mortality. Submitted.
1. Doan T, Hinterwirth A, Arzika AM, et al. . Mass Azithromycin Distribution and Community Microbiome: A Cluster-Randomized Trial. Open forum infectious diseases 2018;5:ofy182. - PMC - PubMed
1. Lakin SM, Dean C, Noyes NR, et al. . MEGARes: an antimicrobial resistance database for high throughput sequencing. Nucleic acids research 2017;45:D574-d80. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Keenan JD, Bailey RL, West SK, et al. . Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. N Engl J Med 2018;378:1583-92. - PMC - PubMed

[2] Keenan JD, Bailey RL, West SK, et al. . Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. N Engl J Med 2018;378:1583-92. - PMC - PubMed

[3] O'Brien KS, Emerson P, Hooper PJ, et al. . Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis 2018. - PubMed

[4] O'Brien KS, Emerson P, Hooper PJ, et al. . Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis 2018. - PubMed

[5] Keenan JD, Arzika AM, Abdou A, Maliki R, Kane S, Cook C, Lebas E, Lin Y, Ray KJ, O’Brien KS, Doan T, Oldenburg C, Emerson PM, Porco TC, Lietman TM. MORDOR II: Persistence of Benefit of Azithryomcin for Childhood Mortality. Submitted.

[6] Keenan JD, Arzika AM, Abdou A, Maliki R, Kane S, Cook C, Lebas E, Lin Y, Ray KJ, O’Brien KS, Doan T, Oldenburg C, Emerson PM, Porco TC, Lietman TM. MORDOR II: Persistence of Benefit of Azithryomcin for Childhood Mortality. Submitted.

[7] Doan T, Hinterwirth A, Arzika AM, et al. . Mass Azithromycin Distribution and Community Microbiome: A Cluster-Randomized Trial. Open forum infectious diseases 2018;5:ofy182. - PMC - PubMed

[8] Doan T, Hinterwirth A, Arzika AM, et al. . Mass Azithromycin Distribution and Community Microbiome: A Cluster-Randomized Trial. Open forum infectious diseases 2018;5:ofy182. - PMC - PubMed

[9] Lakin SM, Dean C, Noyes NR, et al. . MEGARes: an antimicrobial resistance database for high throughput sequencing. Nucleic acids research 2017;45:D574-d80. - PMC - PubMed

[10] Lakin SM, Dean C, Noyes NR, et al. . MEGARes: an antimicrobial resistance database for high throughput sequencing. Nucleic acids research 2017;45:D574-d80. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger

Affiliations

Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger

Authors

Affiliations

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Medical

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

Associated data

Related information

LinkOut - more resources

Full Text Sources

Medical